ImprimisRx has agreed to a product supply agreement with Vision Center Network of America (VCNA). The agreement will make ImprimisRx a VCNA preferred provider for a variety of surgical formulations, including a portfolio of topical and injectable products. VCNA is a clinically integrated network (CIN) of ophthalmic ambulatory surgery centers (ASCs) currently serving patients primarily in the New York and New Jersey area. VCNA currently serves nine ophthalmic ASCs and over 200 ophthalmologists who perform an estimated 100,000 surgical procedures annually in the region. Through the use of its proprietary database, VCNA tracks purchasing volume and patterns for surgical injectables and other products for each of its member surgery centers, specifically as it relates to cataract surgery. These data points will, in turn, provide transparency into actual cost per surgical case across each surgery center as well as individual surgeons for benchmarking purposes.
“We are excited to partner with Vision Center Network of America, whose surgery center members are leading providers of vision health and ophthalmic surgical services in the New York and New Jersey area,” John Saharek, President of ImprimisRx, said. “With over 40 ophthalmic topical and injectable formulations and a presence in all 50 states, we are looking forward to fostering a long-term relationship with VCNA as their regional footprint expands.”
“This partnership with ImprimisRx is a natural fit since both companies believe in high-quality healthcare at an affordable price. We look forward to working with the ImprimisRx team, who have been innovators in the ophthalmic space, to better serve our patients,” Dr. Jerome Levy, President and Chairman of the Board of VCNA, said.